Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 46708-558

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 46708-558). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60 Tablets (Sacubitrilvalsartan 24 26 mg)

FDA Label Image

60 Tablets (Sacubitrilvalsartan 49 51 mg)

FDA Label Image

Figure 7 (Sacubitrilvalsartan 7 Figure)

FDA Label Image

60 Tablets (Sacubitrilvalsartan 97 103 mg)

This text provides information about Sacubitril and Valsartan tablets, each containing 97mg of Sacubitril and 103mg of Valsartan. The usual dosage instructions are not provided, so it is recommended to refer to prescribing information. The tablets should be stored at a temperature between 15-30°C, protected from moisture, and kept out of reach of children. The text mentions the manufacturer, Alembic Pharmaceuticals Ltd, and includes their contact details. This medication requires a prescription and the packaging contains 60 tablets. The NDC (National Drug Code) number for these tablets is 46708-558-60.*

FDA Label Image

Sacubitrilvalsartan-fig-2 (Sacubitrilvalsartan Fig 2)

FDA Label Image

Figure 1 (Sacubitrilvalsartan Fig1)

This text provides information on the coadministered drugs, including Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HETZ, Metformin, Atorvastatin, and Sildenafil. It mentions the geometric mean ratio and 90% confidence intervals for these drugs. The document also indicates a change relative to a reference.*

FDA Label Image

Figure 3 (Sacubitrilvalsartan Fig3)

This data presents the time to first occurrence of cardiovascular (CV) death or heart failure hospitalizations in a study called PARADIGM-HF. The analysis shows the comparison between two treatments: sacubitril and valsartan versus enalapril. The results indicate a significant difference in favor of sacubitril and valsartan as compared to enalapril, with a p-value of less than 0.0001. The number of individuals at risk over time is also provided for each treatment group.*

FDA Label Image

Figure 4 (Sacubitrilvalsartan Fig4)

This data table provides information on the distribution of various factors in a population, such as age, gender, weight, race, medical conditions, medication use, and outcomes related to heart failure treatments (Sacubitril and Valsartan vs. Enalapril). The table shows the percentage of individuals falling into different subgroups based on these factors and also includes the hazard ratios for the two treatments, with Sacubitril and Valsartan being considered better in this comparison.*

FDA Label Image

Figure 6 (Sacubitrilvalsartan Figur6)

FDA Label Image

Figure 5 (Sacubitrilvalsartan Figure5)

FDA Label Image

Structure (Sacubitrilvalsartan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.